KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Receivables (2016 - 2025)

Acadia Pharmaceuticals has reported Receivables over the past 10 years, most recently at $148.2 million for Q4 2025.

  • Quarterly results put Receivables at $148.2 million for Q4 2025, up 41.58% from a year ago — trailing twelve months through Dec 2025 was $148.2 million (up 41.58% YoY), and the annual figure for FY2025 was $148.2 million, up 41.58%.
  • Receivables for Q4 2025 was $148.2 million at Acadia Pharmaceuticals, up from $139.4 million in the prior quarter.
  • Over the last five years, Receivables for ACAD hit a ceiling of $148.2 million in Q4 2025 and a floor of $51.8 million in Q2 2021.
  • Median Receivables over the past 5 years was $89.3 million (2023), compared with a mean of $89.3 million.
  • Biggest five-year swings in Receivables: fell 8.97% in 2022 and later surged 68.4% in 2023.
  • Acadia Pharmaceuticals' Receivables stood at $65.3 million in 2021, then fell by 3.46% to $63.1 million in 2022, then surged by 62.25% to $102.4 million in 2023, then rose by 2.29% to $104.7 million in 2024, then soared by 41.58% to $148.2 million in 2025.
  • The last three reported values for Receivables were $148.2 million (Q4 2025), $139.4 million (Q3 2025), and $119.7 million (Q2 2025) per Business Quant data.